Medizinische Universität Graz - Research portal
Selected Publication:
Gretzer, B; Maricic, N; Respondek, M; Schuligoi, R; Peskar, BM.
Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge.
Br J Pharmacol. 2001; 132(7):1565-1573
Doi: 10.1038/sj.bjp.0703955
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-authors Med Uni Graz
- Schuligoi Rufina
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- 1. Effects of the cyclo-oxygenase (COX)-1 inhibitor SC-560 and the COX-2 inhibitors rofecoxib and DFU were investigated in the normal stomach and after acid challenge. 2. In healthy rats, neither SC-560 nor rofecoxib (20 mg kg(-1) each) given alone damaged the mucosa. Co-treatment with SC-560 and rofecoxib, however, induced severe lesions comparable to indomethacin (20 mg kg(-1)) whereas co-administration of SC-560 and DFU (20 mg kg(-1) each) had no comparable ulcerogenic effect 5 h after dosing. 3. SC-560 (20 mg kg(-1)) inhibited gastric 6-keto-prostaglandin (PG) F(1alpha) by 86+/-5% and platelet thromboxane (TX) B(2) formation by 89+/-4% comparable to indomethacin (20 mg kg(-1)). Rofecoxib (20 mg kg(-1)) did not inhibit gastric and platelet eicosanoids. 4. Intragastric HCl elevated mucosal mRNA levels of COX-2 but not COX-1. Dexamethasone (2 mg kg(-1)) prevented the up-regulation of COX-2. 5. After acid challenge, SC-560 (5 and 20 mg kg(-1)) induced dose-dependent injury. Rofecoxib (20 mg kg(-1)), DFU (5 mg kg(-1)) and dexamethasone (2 mg kg(-1)) given alone were not ulcerogenic but aggravated SC-560-induced damage. DFU augmented SC-560 damage 1 but not 5 h after administration whereas rofecoxib increased injury after both treatment periods suggesting different time courses. 6. Gastric injurious effects of rofecoxib and DFU correlated with inhibition of inflammatory PGE(2). 7. The findings show that in the normal stomach lesions only develop when both COX-1 and COX-2 are inhibited. In contrast, during acid challenge inhibition of COX-1 renders the mucosa more vulnerable suggesting an important role of COX-1 in mucosal defence in the presence of a potentially noxious agent. In this function COX-1 is supported by COX-2. In the face of pending injury, however, COX-2 cannot maintain mucosal integrity when the activity of COX-1 is suppressed.
- Find related publications in this database (using NLM MeSH Indexing)
- Animals -
- Cyclooxygenase 1 -
- Cyclooxygenase 2 -
- Cyclooxygenase 2 Inhibitors -
- Cyclooxygenase Inhibitors - pharmacology
- Dinoprostone - metabolism
- Dose-Response Relationship, Drug - metabolism
- Furans - pharmacology
- Gastric Mucosa - drug effects
- Gene Expression Regulation, Enzymologic - drug effects
- Hydrochloric Acid - pharmacology
- Indomethacin - pharmacology
- Isoenzymes - antagonists and inhibitors
- Lactones - pharmacology
- Male - pharmacology
- Membrane Proteins - pharmacology
- Prostaglandin-Endoperoxide Synthases - genetics
- Pyrazoles - pharmacology
- RNA, Messenger - drug effects
- Rats - drug effects
- Rats, Wistar - drug effects
- Stomach - drug effects
- Sulfones - drug effects
- Find related publications in this database (Keywords)
- cyclo-oxygenase-1
- cyclo-oxygenase-2
- gastric damage
- rofecoxib
- DFU
- SC-560
- gastric 6-keto-prostaglandin F-1 alpha
- platelet thromboxane
- inflammatory prostaglandin E-2
- non-steroidal anti-inflammatory drugs